After an appeal to the Federal Circuit, Defendant Arthrex, Inc. (“Arthrex”) filed a motion to reopen the judgment under FRCP 60(b). Arthrex premised its motion on the argument that the judgment should be reopened in light of the Supreme Court’s recent holding in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 135 S.Ct. 831 (2015).
Plaintiffs Smith & Nephew, Inc. and John Hayhurst (collectively “S&N”) had appealed the district court’s decision to grant Arthrex’s motion for judgment as a matter of law. As set forth by the district court, under the case law in effect at the time of the appellate decision, the Federal Circuit reviewed all aspects of the district court’s claim construction de novo. The Federal Circuit ultimately reversed the decision granting Arthrex’s motion for judgment as a matter of law.
Continue reading